GnRHa for adhesion formation after uterine serosal injury in an euestrogenic milieu.
OBJECTIVE
To assess whether the adhesion-preventing effect of gonadotropin-releasing hormone agonist (GnRHa) is through hypoestrogenism.


METHODS
Four groups of previously ovariectomized rats received various combinations of depot leuprolide acetate injection (3.75 mg/kg/mo) subcutaneously, conjugated equine estrogens (50 micrograms/kg/d) orally and phosphate-buffered saline injection subcutaneously, yielding group 1, saline only; group 2, saline and conjugated equine estrogens; group 3, depot leuprolide acetate only; and group 4, depot leuprolide acetate and conjugated equine estrogens. Surgical adhesions were induced by monopolar cautery on the right uterine horn through laparotomy and were then scored on day 21 after surgery.


RESULTS
Adhesion scores for rats that received conjugated equine estrogens and saline were significantly higher than scores of those given conjugated equine estrogens and depot leuprolide acetate, depot leuprolide acetate only and saline only (P = .019, .026 and .027, respectively). However, there was no significant difference in the adhesion scores for these three groups.


CONCLUSIONS
Hypoestrogenism results in the development of fewer peritoneal adhesions postoperatively. Our findings also indicated that other mechanisms, in addition to those inducing hypoestrogenism, are at work in the adhesion-preventing effects of GnRHa therapy.
Ergeneli
M H
MH
Department of Obstetrics and Gynecology, School of Medicine, Baskent University, Ankara, Turkey.
Kuscu
E
E
Zeyneloglu
H B
HB
Haberal
A
A
Erdogan
M
M
D000818:Animals; D003692:Delayed-Action Preparations; D004966:Estrogens, Conjugated (USP) / Q000008:administration & dosage / Q000494:pharmacology*; D005260:Female; D006736:Horses; D016729:Leuprolide / Q000008:administration & dosage / Q000627:therapeutic use*; D010052:Ovariectomy; D011183:Postoperative Complications / Q000517:prevention & control; D051381:Rats; D017208:Rats, Wistar; D000267:Tissue Adhesions / Q000517:prevention & control*; D014591:Uterine Diseases / Q000517:prevention & control*
D003692:Delayed-Action Preparations; D004966:Estrogens, Conjugated (USP); D016729:Leuprolide